One finding, followed all the way through.
A genomic result is never contained to the person who receives it. It moves through leave policy, the manager, benefits, finance, and the limits of the health system. Here is a single finding traced across each, and what a prepared organization does differently at every step. The people are composite. The mechanics are real.
The employee's own result
Set the stage. A director leads a major, time-critical initiative, the kind with a board deadline and no obvious backup. A young cousin is diagnosed with cancer, the kind of early case that flags a family, so she uses the screening your plan covers and learns she carries a BRCA1 variant. She feels completely well. Nothing about her work has changed, and everything about her year just did.
Here is where that single result lands inside your organization.
She now faces heightened surveillance, decisions about risk-reducing surgery, and conversations with siblings and children about their own risk. It is a heavy, ongoing process layered on top of a demanding role, and she may share none of it at work.
He sees a strong performer suddenly distracted and taking time out. By law he cannot ask about genetic information, and he has had no guidance on what he may ask, what he must not, or where to point her.
Surveillance means recurring appointments. Risk-reducing surgery, if she chooses it, can mean weeks of recovery. Preventive and surveillance care sits in a gray zone that standard sick-leave and FMLA policies were not written for.
Because she is central to a critical initiative, her divided attention is not a private matter for the business. Coverage and succession need thinking through.
She needs genetic counseling to make sense of the result. The national supply is thin, and many patients wait months for an appointment. A policy that simply refers people out sends them into that queue.
How this is handled becomes a signal to everyone watching. Mishandle one person's privacy and the whole workforce learns not to trust the company with anything sensitive.
The same shift, a different shape
The finding does not have to be the employee's own to reach your organization. Two common variations land very differently.
An employee's spouse, a dependent on your plan, is found to carry a hereditary cardiac variant and enters cardiology, monitoring, and a possible implanted device. The care cost is directly yours because you cover the spouse. And although it is not the employee's own body, the employee is the caregiver, the coordinator, and the one who brings the fear to work.
A high performer learns his father and sister both carry Lynch syndrome after his father's diagnosis. He may not test himself for a year, but he is coordinating care and holding the weight, and his output quietly drops for months. None of it appears on your claims data, and no one connects the dip to its cause.
The counselor bottleneck
The instinct is to make this a benefit and refer affected people to outside genetic counseling. At a few cases a year, that works. At the scale these numbers imply for a large workforce, it collides with a national shortage.
If a meaningful share of a large workforce needs counseling and the national supply is this thin, a referral-only policy quietly pushes your people into a months-long wait at the worst possible moment. The smarter posture for a large employer is not to become a clinic, but to invest ahead of demand in navigation, education, and internal capability, so people are supported while they wait for the specialist care that will always sit outside the company.
How finance would model it
Finance does not need a precise number to plan for this. It needs the shape of the exposure, which comes in the same three parts, each modeled differently.
Affected covered lives times expected care cost. The population from the estimator, weighted by how many findings turn into surveillance, surgery, or specialty treatment. This is the number a self-funded actuary can bound.
Affected employees times productivity drag times duration. Harder to see and usually larger than expected, because it includes the relatives-beyond-the-plan cases that never touch claims data.
A one-time capability build. Policy, manager guidance, navigation, and education. Modeled as a fixed project cost, not an ongoing liability, and far smaller than the disruption it prevents.
Only the first part scales with headcount. For all but the largest self-funded employers, it is usually the smallest of the three. The indirect and transition costs are larger and less visible.
And the direction is up. Cheaper sequencing and faster variant discovery, now accelerated by machine learning, mean the same test flags more people each year, and some told they were clear are later reclassified. Model this as a rising line, not a fixed cost.
None of this requires knowing anyone's result
Every prepared response above happens without the company ever learning what any individual carries. Readiness is a set of decisions made in advance: how leave treats preventive care, what a manager does in the moment, where people are pointed for support, how privacy is held, and how finance frames the exposure. Made early, these are quiet and inexpensive. Made in the moment, they are a scramble.
Start the conversationScenarios are composite and do not depict real individuals. Genetic counselor workforce figures: Bellaiche et al., Frontiers in Oncology 2021, approximately 1.5 counselors per 100,000; Jenkins et al., Genetics in Medicine 2021, on appointment wait times; Ormond et al., Genetics in Medicine Open 2024, on global workforce growth. Prevalence range: PREDICT study, Genetics in Medicine 2026, and broader genome-screening cohorts, 2025 to 2026. This page is a strategic point of view and does not constitute legal, medical, or actuarial advice.